+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation

  • ID: 2237721
  • Book
  • January 2013
  • 536 Pages
  • Elsevier Science and Technology
1 of 3

Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. By providing an overview of the immune biology of HSCT, an explanation of immune rejection, and detail on antigens and their role in HSCT success, this book embraces biologists and clinicians who need a broad view of the deeply complex processes involved. It then moves on to discuss the immunobiology mechanisms that influence graft-versus-host disease (GVHD), graft-versus-leukemia (GVL) effect, and transplantation success. Using illustrative figures, highlighting key issues, describing recent successes and discussing unanswered questions, this book sums up the current state of HSCT to enhance the prospects for the future.

Allogeneic HSCT is a medical procedure in which a patient receives blood-forming stem cells from a genetically similar but not identical donor. This procedure is commonly performed for people with diseases of the blood, bone marrow, or certain cancers, but it remains risky with many possible complications. As such, experimental practice is reserved for preclinical animal models including the mouse and dog.

These animal models have been essential in developing transplant protocols, including preclinical testing of conditioning regimens, treatment of GVHD, and understanding the pathology of GVHD as well as the immunological mechanisms of GVHD and GVL effect. However, recent research has revealed significant species differences between humans and animal models that must be considered when relating animal model studies to clinical allogeneic HSCT scenarios.

  • Brings together perspectives leading laboratories and clinical research groups to highlight advances from bench to the bedside
  • Guides readers through the caveats that must be considered when drawing conclusions from studies with animal models before correlating to clinical allogeneic HSCT scenarios
  • Categorizes the published advances in various aspects of immune biology of allegeneic HSCT to illustrate opportunities for clinical applications

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3
Overview of the immune biology of HSCT; The HLA system; Minor Histocompatibility antigens; In vivo imaging of GVHD and GVL; Immune rejection; The basis of immune deficiency; Tumor associated antigens; Impact of the conditioning regimen; Dendritic cells in GVHD; Costimulatory molecules in GVHD and GVL; Conventional T cells in GvHD and GVL; Regulatory T cells in GVHD and GVL; Th17 in GVHD and GVL; B cells in GVHD and GVL; Cytokines in GVHD and GL; Chemokines in GVHD and GL; Intracellular sensors; Proteomics in GVHD and GVL; The endothelium in GVHD and GVL; Immune Biology of the future
Note: Product cover images may vary from those shown
3 of 3
Socie, Gerard
Dr. Gerard Socie's main field of expertise (clinical and biological); allogeneic stem cell transplantation with special focus on graft-versus-host disease and study of late effects, aplastic anemia with special focus on PNH, and Fanconi anemia. He is GCP certified (last May 2017) and the department head and head of transplantation at the Hospital Saint Louis, University of Paris VII.
Blazar, Bruce R.
Note: Product cover images may vary from those shown